Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Hereditary Diffuse Gastric Cancer

Gastrointestinal

Hereditary Diffuse Gastric Cancer (HDGC) Clinical Trials

Also called HDGC, CDH1 mutation, diffuse-type gastric cancer

Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer predisposition syndrome caused by germline mutations in the CDH1 gene (chromosome 16q22.1) encoding E-cadherin, a calcium-dependent cell adhesion protein essential for cell-cell contact. E-cadherin deficiency impairs cell-cell adhesion, leading to proliferation of individual cancer cells without forming obvious masses, creating the diffuse-type gastric cancer difficult to detect with conventional endoscopy.

In plain words, hereditary diffuse gastric cancer is passed down in families and raises the chance of a stomach cancer that is hard to spot. A change in a gene that helps cells stick together is the cause, and women also have a higher chance of breast cancer.

Get an email when new Hereditary Diffuse Gastric Cancer trials open or the FDA decides. Get alerts

Hereditary Diffuse Gastric Cancer

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 1 study with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Hereditary Diffuse Gastric Cancer yet.

Hereditary Diffuse Gastric Cancer has no FDA-approved medicines, 1 open or active clinical trial (1 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

More about Hereditary Diffuse Gastric Cancer

Many CDH1 carriers develop gastric cancer if the stomach is not removed. Lifetime risk estimates range from 42% for men and 33% for women by age 80 in a 2019 study of families found through broader genetic testing (Roberts, JAMA Oncology) to 70% for men and 56% for women in MedlinePlus Genetics, and the 2020 international guidelines recognize that risk varies between families (Blair, Lancet Oncology). Gastric cancer in HDGC families tends to be early-onset (median age 40-50 years, much younger than sporadic gastric cancer median of 65+ years) and typically presents with advanced stage disease due to insidious diffuse infiltration.

Keep reading about Hereditary Diffuse Gastric Cancer

HDGC gastric cancer has worse prognosis than sporadic diffuse gastric cancer with lower resection rates due to extensive peritoneal involvement. Some CDH1 mutations (particularly truncating mutations) also increase lobular breast cancer risk in female carriers (40% by age 70-80), distinct from intestinal breast cancer subtypes. The insidious nature of diffuse gastric cancer makes early detection challenging with conventional endoscopy, as early disease appears as subtle thickening without discrete masses.

What are the symptoms of Hereditary Diffuse Gastric Cancer?

These are common symptoms of Hereditary Diffuse Gastric Cancer, and how strong they are varies from person to person.

  • Diffuse-type gastric adenocarcinoma
  • No early warning signs in early disease
  • Dyspepsia and upper abdominal discomfort in advanced cases
  • Weight loss and anemia
  • Associated lobular breast cancer in some families
  • Metastatic disease in advanced cases

Who gets Hereditary Diffuse Gastric Cancer?

Estimates of stomach cancer risk for CDH1 carriers vary. MedlinePlus Genetics gives a lifetime chance of 70% for men and 56% for women. A 2019 study of 41 families found through clinical and multigene panel genetic testing at a commercial laboratory estimated 42% for men and 33% for women by age 80, and its authors say earlier estimates were likely too high because they came from families with several stomach cancers (Roberts, JAMA Oncology). Women carriers also face a higher risk of lobular breast cancer. Early-onset gastric cancer common, occurring in 20s-40s in some carriers; some patients develop cancer by age 30. Autosomal dominant inheritance with approximately 50% of offspring of affected parents inheriting mutation.

Specific CDH1 mutation type (truncating vs. missense, location) influences penetrance and organ involvement. Ethnic and geographic variations in founder mutations documented (specific mutations common in certain populations). Inactivating mutations required (single allele sufficient due to haploinsufficiency). Approximately 5-10% of early-onset gastric cancer cases carry CDH1 mutations.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Hereditary Diffuse Gastric Cancer

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Hereditary Diffuse Gastric Cancer resources

Reputable organizations and medical references for learning more about Hereditary Diffuse Gastric Cancer, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Hereditary Diffuse Gastric Cancer

Use this Hereditary Diffuse Gastric Cancer clinical trial finder to see the 1 study recruiting patients in the United States and worldwide, with eligibility criteria in plain English. It does not test a treatment; it follows patients over time. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

1 active trial worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenNo updates in a whileNCT05126290

CTNNA1 Familial Expansion Study

Intervention: Collection of personal and family history from CAFÉ Study participants

Sponsor: Abramson Cancer Center at Penn Medicine

The goal of the CAFÉ Study is to determine the cancer risks associated with germline CTNNA1 loss-of-function variants.

Ages 18 Years+1 location
Started Mar 2021Updated 9 months agoEst. Jan 2028 (~1y 1m)
Find Hereditary Diffuse Gastric Cancer trials near you, ranked by distance →
Active trial locations1 city in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Mar 2021 to Jan 2028
2022
2024
2026
2028
now
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Hereditary Diffuse Gastric Cancer trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Hereditary Diffuse Gastric Cancer foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Hereditary Diffuse Gastric Cancer patient communities

Facebook groups, Reddit communities and YouTube channels where Hereditary Diffuse Gastric Cancer patients, caregivers and advocacy groups talk.

Companies developing Hereditary Diffuse Gastric Cancer treatments

Drugmakers that list Hereditary Diffuse Gastric Cancer in their rare disease portfolio, 3 in all.

Questions people ask about Hereditary Diffuse Gastric Cancer